引用文献
[1] Klotz L, Boccon-Gibod L N, Andreou C, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. Bju International, 2008, 102(11):1531-1538
[2] Sciarra A, Fasulo A, Ciardi A, et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine, 2016, 95(27): e3845.
[3] Tokiwa S, Shimmura H, Nomura S, et al. Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. Research & Reports in Urology, 2017, 9:225.
[4] Kimura T, Sasaki H, Akazawa K, et al. Gonadotropin-releasing hormone antagonist: A real advantage? Urologic Oncology Seminars & Original Investigations, 2015, 33(7):322-328.
[5] Xie L, Li J, Wang X. Updates in prostate cancer detections and treatments – Messages from 2017 EAU and AUA. Asian Journal of Urology, 2017, 5(1):3-7.
[6] Alireza H S, Fatemeh R, Ali A S, et al. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Medical Journal of the Islamic Republic of Iran, 2016, 30(1):317-317.
[7] Albertsen P C, Klotz L, Tombal B, et al. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. European Urology, 2014, 65(3):565-573.
[8] Klotz L1, Miller K2, Crawford ED, et al, Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists，Eur Urol. 2014 Dec;66(6):1101-8.
[9] Gittelman M, Pommerville P J, Persson B E, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. Journal of Urology, 2008, 180(5):1986-1992.